Press releases

Oxford BioMedica plc Board Change

-- Appointment of New Non-Executive Director --

Oxford, UK – 3 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces the appointment of Martin Diggle as a non-Executive Director of the Company, effective as of 4 October 2012.

Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Oxford BioMedica’s largest shareholder.  An investment professional with over 29 years’ experience in investment banking and fund management, Martin has extensive, first-hand knowledge of the global financial markets.  Martin is an expert in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003.  He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade.  Martin holds a master’s degree in Philosophy, Politics and Economics from University of Oxford. 
 
Nick Rodgers, Chairman of Oxford BioMedica, said: “Martin has been a long-term supporter of Oxford BioMedica and I am delighted to welcome him to the Board.  With a wealth of financial investment experience and a strong international reputation, Martin’s contribution will be invaluable as we continue to attract further investment into the Company and implement our growth strategy.”

There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.

-Ends-

Notes to editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Tel: +44 (0)1865 783 000

 

Financial and corporate communications enquiries:

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton

Tel: +44 (0)20 3709 5700

 

Peel Hunt (Joint Corporate Brokers):

James Steel/Christopher Golden

Tel: +44 (0)20 7418 8900

 

WG Partners (Joint Corporate Brokers):

David Wilson/Claes Spang

Tel: +44 (0)20 3705 9321